Adaptive Biotechnologies IPO

Adaptive Biotechnologies is a biotechnology company specializing immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.

Register for Details

For more details on financing and valuation for Adaptive Biotechnologies, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Adaptive Biotechnologies

Forge green plus iconForge green minus icon

What is Adaptive Biotechnologies's IPO price?

Adaptive Biotechnologies's IPO price is $4.07 as of 1/18/24.
Forge green plus iconForge green minus icon

What is Adaptive Biotechnologies's funding to date?

Adaptive Biotechnologies has raised $561.37MM to date.
Forge green plus iconForge green minus icon

When was Adaptive Biotechnologies founded?

Adaptive Biotechnologies was founded in 2009.

Adaptive Biotechnologies Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
1/4/2018 Series F-1 $45MM raised $XXX.XX $XXX.XX
5/6/2015 Series F $195.1MM raised $XXX.XX $XXX.XX
1/22/2015 Series E1 $105.12MM raised $XXX.XX $XXX.XX
1/21/2015 Series E $93.75MM raised $XXX.XX $XXX.XX
7/29/2014 Series D $107MM raised $XXX.XX $XXX.XX
7/9/2013 Series C $5.02MM raised $XXX.XX $XXX.XX
6/2/2011 Series B $5.82MM raised $XXX.XX $XXX.XX
3/24/2010 Series A $4.55MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Nov 15, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.